NCT06513104View on ClinicalTrials.gov

A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 18, 2024

Primary Completion Date

September 9, 2025

Study Completion Date

October 1, 2025

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

NNC0519-0130

NNC0519-0130 will be administered subcutaneously.

DRUG

Levonorgestrel + Ethinylestradiol

Levonorgestrel + Ethinylestradiol will be administered orally.

DRUG

Paracetamol

Paracetamol will be administered orally.

Trial Locations (1)

14050

Parexel International GmbH, Berlin

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY